Acrobiosystems Co

Acrobiosystems Co Altman Z-Score

The Altman Z-Score of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 17.47. In the previous year, Altman Z-Score was 19.94 — a change of -12.42% (lower).

Altman Z-Score

17.47

YoY

-12.42%

Last updated:

Altman Z-Score of Acrobiosystems Co is 2025 17.47 . Altman Z-Score of Acrobiosystems Co was 2024 19.94 . It decreases by -12.42% lower compared to the previous year.

The Acrobiosystems Co Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
583.08 CNY
Jan 1, 2019
368.18 CNY
Jan 1, 2020
146.45 CNY
Jan 1, 2021
75.46 CNY
Jan 1, 2022
35.85 CNY
Jan 1, 2023
26.73 CNY
Jan 1, 2024
19.94 CNY
Jan 1, 2025
17.47 CNY
The Acrobiosystems Co Altman Z-Score history
YEARAltman Z-ScoreYoY
17.47-12.42%
19.94-25.40%
26.73-25.42%
35.85-52.49%
75.46-48.48%
146.45-60.22%
368.18-36.86%
583.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Altman Z-Score of Acrobiosystems Co is 17.47 in 2025.

On Eulerpool you can find the complete historical development of Altman Z-Score Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co